Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters

Paolo De Simone; Jessica Bronzoni; Caterina Martinelli

doi:10.17235/reed.2022.8902/2022

Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters

Rev Esp Enferm Dig. 2022 Jun;114(6):312-313. doi: 10.17235/reed.2022.8902/2022.

Authors

Paolo De Simone¹, Jessica Bronzoni¹, Caterina Martinelli¹

Affiliation

¹ Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Italia.

PMID: 35545915
DOI: 10.17235/reed.2022.8902/2022

Abstract

The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantages of everolimus (EVR)-facilitated tacrolimus (TAC) minimization versus TAC in combination with mycophenolate mofetil (MMF) after liver transplantation (LT).

Publication types

Introductory Journal Article
Editorial
Comment

MeSH terms

Drug Therapy, Combination
Everolimus* / therapeutic use
Humans
Kidney / drug effects
Kidney / physiology
Liver Transplantation*
Multicenter Studies as Topic
Mycophenolic Acid* / therapeutic use
Tacrolimus / therapeutic use

Substances

Everolimus
Mycophenolic Acid
Tacrolimus